AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. LCTX
  4. [SCHEDULE 13G/A] Lineage Cell Therapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Lineage Cell Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source:

Stock LCTX logo
Lineage Cell The

NYSE:LCTX

LCTX Rankings

#4003 Ranked by Market Cap
N/A Ranked by Dividends

LCTX Latest News

Aug 12, 2025
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 5, 2025
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
Aug 4, 2025
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
Jun 23, 2025
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
Jun 5, 2025
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

LCTX Latest SEC Filings

Aug 12, 2025
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] Lineage Cell Therapeutics, Inc. Reports Material Event
Jul 3, 2025
[Form 4] Lineage Cell Therapeutics, Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] Lineage Cell Therapeutics, Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] Lineage Cell Therapeutics, Inc. Insider Trading Activity

LCTX Stock Data

230.64M
227.40M
0.42%
48.24%
12.3%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CARLSBAD